Zobrazeno 1 - 7
of 7
pro vyhledávání: '"J W Smith nd"'
Autor:
P M Guyre, Dan L. Longo, C H Ewel, J W Smith nd, William C. Kopp, C Main, W G Alvord, Ronald G. Steis, W J Urba
Publikováno v:
Journal of Immunotherapy. 13:181-190
Interferon-gamma (IFN-gamma) is a potent monocyte/macrophage activating agent that in animal models exhibits a bell-shaped dose-response curve of immunomodulatory activity and antitumor efficacy. Previous clinical trials of IFN-gamma conducted at the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5e3968a14e5c6d08f9324931e75829bf
https://doi.org/10.1097/00002371-199304000-00005
https://doi.org/10.1097/00002371-199304000-00005
Autor:
Kevin C. Conlon, W J Urba, J W Smith nd, Brendan D. Curti, John E. Janik, Robert G. Fenton, Ronald G. Steis, W. H. Sharfman, L J Elwood, Langdon L. Miller
Publikováno v:
Journal of Clinical Oncology. 10:1141-1152
PURPOSE A phase I trial was undertaken because interleukin-1 alpha (IL-1 alpha) possesses antiproliferative, immunostimulatory, antiinfection, myeloprotective, and myelorestorative properties that could be beneficial in cancer treatment. PATIENTS AND
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::463aa858e965d2e7f83fe52780fbc12b
https://doi.org/10.1200/jco.1992.10.7.1141
https://doi.org/10.1200/jco.1992.10.7.1141
Autor:
J W Smith nd, Michael J. Hawkins, Jeffrey W. Clark, S Nerenstone, Ronald G. Steis, A Martin, Dan L. Longo, S P Creekmore, Jeffry B. Lawrence, W J Urba
Publikováno v:
Journal of Clinical Oncology. 8:721-730
Fifteen patients with hairy cell leukemia (HCL) were treated with deoxycoformycin (pentostatin; dCF) (4 mg/m2 intravenous [IV] every week x 3) and recombinant interferon-alpha 2a (rIFN-alpha 2a) (3 x 10(6) units subcutaneously [SC] daily x 4 weeks) i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6932bb8120ee66649a0752e31f43b703
https://doi.org/10.1200/jco.1990.8.4.721
https://doi.org/10.1200/jco.1990.8.4.721
Autor:
W J Urba, P Brant-Zawadski, Mary L. Disis, William Wood, E Johnson, J W Smith nd, T Doran, Deric D. Schoof
Publikováno v:
Advances in Experimental Medicine and Biology ISBN: 9781461374442
Tumor-associated antigens have been identified on a variety of human neoplasms. Each of these antigens may be able to serve as a target for an immune response, the result of which would be elimination of the tumor cell. An essential component of this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::869ee437b0539b8c92a06c379e92f8f0
https://doi.org/10.1007/978-1-4615-5357-1_79
https://doi.org/10.1007/978-1-4615-5357-1_79
Autor:
Robert G. Fenton, J W Smith nd, John E. Janik, Barry L. Gause, C Hawk, Dan L. Longo, S P Creekmore, M Sznol, Jon Holmlund, G Powers, Langdon L. Miller, Brendan D. Curti, A C Ochoa, W J Urba, W. H. Sharfman, P Kremers, William Kopp, W G Alvord
Publikováno v:
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 19(4)
The adoptive transfer of anti-CD3-stimulated T killer (T-AK) cells was tested with different bolus and infusional interleukin-2 (IL-2) regimens, and anti-CD3 stimulation procedures to determine immunologic and antitumor effects in patients with a var
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b05ad91db882c5ab412e173dc7640833
https://pubmed.ncbi.nlm.nih.gov/8877723
https://pubmed.ncbi.nlm.nih.gov/8877723
Autor:
Barry L. Gause, Brendan D. Curti, Dan L. Longo, Augusto C. Ochoa, W G Alvord, Kevin C. Conlon, Robert G. Fenton, S P Creekmore, J W Smith nd, Jon Holmlund
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 11(4)
PURPOSE This study describes the physiologic and biologic effects resulting from the adoptive transfer of ex vivo anti-CD3-stimulated T-killer cells (T-AK) to patients with advanced cancer in combination with interleukin-2 (IL-2). METHODS Autologous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c57f02270272cc2d2a19e5a3d3d9eab2
https://pubmed.ncbi.nlm.nih.gov/8355052
https://pubmed.ncbi.nlm.nih.gov/8355052
Autor:
M Sznol, Robert G. Fenton, John E. Janik, J W Smith nd, Ronald G. Steis, Dan L. Longo, S P Creekmore, W G Alvord, W. H. Sharfman, William C. Kopp
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 11(1)
PURPOSE This phase I study was conducted to determine the maximum-tolerated dose (MTD) and the immunologic properties of levamisole in cancer patients when administered alone and in combination with interferon gamma (IFN-gamma). PATIENTS AND METHODS
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::beb19928efdaba18549502774d961921
https://pubmed.ncbi.nlm.nih.gov/8418223
https://pubmed.ncbi.nlm.nih.gov/8418223